Pharmacy Benefit Manager Reform vs. Direct Drug Plans

Prescription drug pricing in America has a talent for being both expensive and weird. A patient can walk into a pharmacy, hand over an insurance card, and somehow pay more than the cash price online. An employer can spend millions on pharmacy benefits and still struggle to explain where the money actually went. A local pharmacy can fill prescriptions all day and still feel like it is losing a knife fight with a spreadsheet. That confusion is exactly why the debate over pharmacy benefit manager reform vs. direct drug plans has moved from policy circles into boardrooms, pharmacies, and kitchen-table conversations.

At the center of the storm are pharmacy benefit managers, or PBMs. These companies manage prescription drug benefits for health plans, employers, Medicare Part D plans, and other payers. In theory, PBMs are supposed to negotiate discounts, build formularies, process claims, and keep drug spending under control. In practice, critics argue that the current PBM model often rewards opacity, encourages rebate-driven choices, and can leave patients paying based on inflated list prices rather than lower net prices.

Now two big ideas are competing for attention. One is PBM reform: keep PBMs in the system, but regulate them harder, make them more transparent, ban or limit spread pricing, and delink compensation from drug prices. The other is the rise of direct drug plans: models that try to bypass parts of the traditional PBM machinery through direct purchasing, cost-plus arrangements, carve-outs, modular contracting, or manufacturer-to-employer programs.

So which approach is better? The honest answer is not nearly as satisfying as a viral headline. PBM reform can fix some of the worst incentives in the current system, but it does not automatically create a beautifully simple drug market by sunrise on Monday. Direct drug plans can cut through layers of markup and deliver clearer pricing, but they do not magically replace every function PBMs perform. For employers, patients, pharmacies, and policymakers, the smarter question is not “Which side wins?” It is “Which model works best for which drugs, which populations, and which plan goals?”

What PBMs Actually Do

Before comparing models, it helps to define the job. PBMs sit in the middle of the prescription drug supply chain. They negotiate rebates and discounts with manufacturers, create formularies that determine which drugs are covered, contract with pharmacies, process claims, and manage utilization tools such as prior authorization and step therapy.

That middleman role is not inherently evil. Plenty of middlemen do useful work. Real estate agents, freight brokers, and people who somehow find concert tickets five minutes before a show all serve a purpose. PBMs can reduce administrative burden and help plan sponsors aggregate purchasing power. They also help manage specialty drug distribution, mail-order services, and pharmacy networks across large populations.

But the biggest criticism is that many PBM incentives do not line up neatly with what patients or plan sponsors want. When PBM compensation is tied to rebates or list-price dynamics, the system can favor drugs with bigger rebate opportunities rather than the lowest true net cost. That is one reason critics say PBM contracts can make the drug benefit look cheaper in one place while quietly moving costs somewhere else.

Why PBM Reform Has So Much Momentum

The momentum behind PBM reform is not coming from one ideological camp. It has become one of those rare health policy topics that can make progressives, conservatives, employers, independent pharmacists, and patient advocates all nod at the same time. That is usually a sign that something structural is bothering a lot of people.

Several complaints come up again and again. First is rebate opacity. Employers and health plans often cannot fully see how much rebate value is created, retained, passed through, or offset elsewhere in the contract. Second is spread pricing, where a PBM charges a payer more for a drug than it reimburses the pharmacy and keeps the difference. Third is steering, in which vertically integrated PBMs may direct patients toward affiliated mail-order, specialty, or retail pharmacies. Fourth is formulary distortion, where higher-list-price drugs with larger rebates can look more attractive inside the system than lower-priced alternatives.

Federal scrutiny has intensified because the PBM market is highly concentrated. That matters because concentration plus vertical integration can turn pricing complexity into market power. If a few companies control claims processing, pharmacy networks, specialty channels, rebate negotiations, and affiliated insurer relationships, they do not merely participate in the market. They shape it.

Recent reforms reflect that concern. In Medicare Part D, policymakers have already pushed more price concessions to the point of sale so beneficiaries can share in savings sooner. New federal legislation enacted in 2026 also moves toward delinking PBM compensation from a drug’s price and rebates in Part D and adds new transparency and reporting requirements. That is a meaningful shift. It says Washington is no longer satisfied with “trust us, it all nets out eventually.”

What PBM Reform Can Fix

1. It can reduce distorted incentives

When a PBM makes more money from higher-priced products with bigger rebate potential, everyone should at least raise an eyebrow. Delinking compensation from list prices and rebates is designed to reduce that distortion. A flat service fee is not as glamorous as a rebate waterfall, but it is easier to understand and easier to audit.

2. It can improve visibility for employers and plan sponsors

Transparency rules matter because health benefit decisions are only as good as the data behind them. Employers increasingly want line-of-sight into pharmacy claims, dispensing channels, affiliated pharmacy usage, rebate flows, and total enterprise revenue. Reform gives plan sponsors more information to test whether their PBM is actually saving money or merely rearranging invoices in an artistic way.

3. It can help patients at the pharmacy counter

One of the biggest practical wins from recent Medicare changes is the move to reflect more price concessions at the point of sale. That matters because patients do not buy groceries with year-end reconciliations. They buy medication at the counter, often while tired, sick, or trying not to cry in front of the pharmacist. When out-of-pocket costs are based on inflated negotiated prices, patients feel the pain immediately.

4. It can support fairer competition

Stronger oversight can also help independent and community pharmacies by making reimbursement and contracting rules less murky. That matters for access, especially in rural and lower-income areas where the neighborhood pharmacy is not just a place to pick up pills. It is often the closest thing to a walk-in health hub.

Where PBM Reform Falls Short

PBM reform is necessary, but it is not a magic coupon code for the entire drug system. First, many reforms apply initially to Medicare Part D, not the whole commercial market. Private employers may benefit indirectly from market pressure and better contracting norms, but they are not guaranteed instant savings just because Congress tightened rules for Part D.

Second, reform does not eliminate the broader structural drivers of drug spending. High launch prices, specialty drug growth, biologic competition barriers, obesity drugs, cell and gene therapies, and medical-benefit drugs all keep pushing costs upward. Reform can make the middle of the system cleaner, but it does not automatically make the products entering the system cheaper.

Third, transparency alone is not the same thing as affordability. A beautifully detailed report can still end with the phrase “Your spend went up 14%.” Employers need the ability to act on the information, not just admire it in a dashboard.

What Direct Drug Plans Mean

The phrase direct drug plans sounds simple, but it covers several different approaches.

• Direct-to-employer manufacturer programs, where an employer contracts more directly for certain drugs instead of routing every transaction through the traditional PBM structure.
• Cost-plus pharmacy models, often used for generics, where pricing is based on acquisition cost plus a transparent markup and dispensing fee.
• Modular or carved-out pharmacy arrangements, where claims, networks, specialty distribution, utilization management, and rebate services are split across multiple vendors instead of bundled with one PBM.
• Transparent pass-through PBM models, which do not fully bypass PBMs but act more like administrators than rebate-driven middlemen.

These approaches all share one basic idea: cut out hidden layers, expose the economics, and let employers or plan sponsors control more of the design. In newer direct-to-employer models, pricing may be negotiated upfront, with less reliance on delayed rebates. In modular models, the employer gains more control over which vendor handles which function. In cost-plus models, the attraction is simple: the price is the price, not a mystery novel with prior authorization.

Why Direct Drug Plans Are Gaining Attention

Employers are under real pressure. Pharmacy spending has been one of the fastest-growing parts of health benefit costs, and drugs such as GLP-1 therapies have made that pressure impossible to ignore. That is why more employers are evaluating alternatives to traditional PBM contracts, including emerging PBMs, broader revenue disclosure demands, and modular arrangements where different vendors handle different pieces of the pharmacy benefit.

Direct models appeal to employers for three big reasons. First is pricing clarity. Instead of waiting months to understand rebate credits and reconciliation logic, employers can see more of the real transaction. Second is control. Employers can choose targeted solutions for high-cost categories rather than accept a one-size-fits-all arrangement. Third is fiduciary comfort. When benefit leaders know exactly who gets paid, how much, and for what, they sleep a little better.

There is also a cultural appeal here. The direct model feels modern. It promises fewer hidden incentives, fewer handoffs, and fewer moments where a plan sponsor asks, “Why are we paying this much for a generic?” That emotional appeal should not be underestimated. Confusion is expensive.

What Direct Drug Plans Can Do Better

1. They can simplify selected categories

For many generic drugs, a direct or cost-plus model can be refreshingly straightforward. If the product is widely available and does not require complex specialty handling, it may not need a five-layer financial ballet.

2. They can reduce dependence on rebate logic

Direct models are especially attractive when employers believe the rebate game is distracting from the real goal: lower net cost and better patient access. If a plan can buy a drug or arrange access in a way that does not depend on inflated list prices and back-end credits, that may be a win.

3. They can give employers leverage

Even when employers do not fully replace a traditional PBM, the presence of direct alternatives gives them negotiating power. Incumbents suddenly become more willing to offer pass-through terms, better audit rights, cleaner definitions of compensation, or customized channel strategies. Amazing how competitive the market can become when someone threatens to read the contract closely.

Where Direct Drug Plans Can Struggle

Here is the catch: direct drug plans work best when the drug category and operational model fit the strategy. They are not a universal substitute for every PBM function.

Specialty drugs often involve prior authorization, cold-chain logistics, patient support, refill coordination, site-of-care management, and complex monitoring. That is not impossible to unbundle, but it is not as simple as swapping out a spreadsheet tab. Likewise, direct models for obesity drugs may solve one access problem while creating new questions about eligibility rules, adherence, long-term cost management, and integration with the rest of the benefit.

Modular and direct approaches can also introduce fragmentation. If one vendor handles claims, another handles rebates, another handles specialty distribution, another handles navigation, and a fifth manages a direct manufacturer arrangement, the employer may gain control while the member experience gets messier. There is a reason only a smaller share of employers are seriously pursuing modular pharmacy management today: autonomy rises, but complexity rises with it.

Another limitation is scope. A direct model may work beautifully for a narrow slice of drugs and do almost nothing for the rest of the pharmacy spend. That does not make it a bad idea. It just means employers should not confuse a targeted tactic with a total operating system.

PBM Reform vs. Direct Drug Plans: Which One Wins?

If the goal is to fix the broadest share of the market, PBM reform matters more. It targets system-wide incentives, transparency, patient cost-sharing, and contracting practices that affect millions of people. Without reform, even smart employers face a market shaped by concentrated players and opaque economics.

If the goal is to create faster, cleaner savings in selected categories, direct drug plans may move faster. Employers do not have to wait for Washington to finish arguing over commas in a statute. They can test direct purchasing, pass-through models, cost-plus arrangements, or category-specific carve-outs now.

For most plan sponsors, the future is probably hybrid. Reform creates better rules for the market. Direct plans create better options within it. One changes the operating environment; the other changes the purchasing strategy.

That hybrid approach looks something like this: use PBM reform and stronger contracting rules to demand transparency, audit rights, and fairer incentive structures; then selectively deploy direct or modular strategies for categories where the math clearly works. In other words, do not choose between fixing the house and opening a window. Sometimes you need both.

Real-World Experiences With PBM Reform and Direct Drug Plans

In the real world, this debate rarely feels theoretical. Employers experience it first as a budgeting problem. A benefits team may start the year thinking its main challenge is medical trend, then discover pharmacy has become the faster-moving headache. The conversation quickly shifts from “How do we manage utilization?” to “Who is actually getting paid here?” Once leaders see how hard it is to trace rebate flows, specialty margins, affiliated pharmacy steerage, and gross-to-net differences, PBM reform stops sounding abstract. It starts sounding like basic governance.

Patients experience the issue more personally and more painfully. They do not usually care whether a price problem came from list-price inflation, formulary placement, rebate design, or a channel preference agreement. They care that one pharmacy quoted one amount, another quoted a second amount, the cash option somehow beat the insurance option, and the prior authorization portal felt like a side quest nobody asked for. For many patients, “reform” simply means fewer surprises and fewer reasons to abandon therapy.

Independent pharmacists often describe the situation as one of constant unpredictability. Reimbursement can feel opaque, retroactive adjustments can make margins uncertain, and competing against PBM-affiliated channels can feel like playing a game in which the referee also owns the other team. That is why pharmacy groups tend to support stronger transparency, limits on spread pricing, and clearer contracting standards. Their experience is not just about revenue; it is about survival and access in communities where local pharmacies close and patients lose a familiar point of care.

Employers experimenting with direct drug plans report a different kind of experience. The biggest upside is often psychological as much as financial: decision-makers can finally see the structure. Upfront pricing, category-specific contracts, and cost-plus logic make the pharmacy benefit easier to explain internally. Finance teams like the predictability. HR teams like being able to describe a program without needing a decoder ring. But these employers also learn quickly that direct models require more hands-on oversight. A cleaner contract can mean a heavier management burden.

Another common experience is that direct models work best when used with discipline. Employers may have success targeting generics, a specialty subset, or a high-profile class like GLP-1s, while leaving the rest of the benefit in a reformed PBM framework. That mixed model can produce real savings and better transparency, but only if member communication is strong. Otherwise, employees are left asking why one drug runs through one channel, another through a different pharmacy, and a third through the old plan. The administrative logic may make perfect sense on paper and still feel chaotic to a family trying to refill prescriptions before dinner.

What ties these experiences together is simple: the old “set it and forget it” pharmacy model is losing credibility. Employers want accountability. Patients want affordability. Pharmacists want fairness. Policymakers want cleaner incentives. PBM reform speaks to those demands at the system level. Direct drug plans speak to them at the purchasing level. That is why this is not a passing trend. It is a broader reset in how people expect prescription benefits to work.

Conclusion

The debate over pharmacy benefit manager reform vs. direct drug plans is really a debate about trust, incentives, and control. PBM reform says the middle of the system needs rules that are clearer, fairer, and less dependent on hidden economics. Direct drug plans say some parts of the system should be bypassed or unbundled when they no longer add enough value.

Both ideas have merit. PBM reform is essential for improving transparency, aligning incentives, and protecting patients and pharmacies in a market dominated by a few large players. Direct drug plans are valuable because they give employers practical alternatives right now, especially in categories where pricing can be simplified and purchasing can be more direct.

The smartest path forward is not ideological. It is operational. Fix the incentives. Demand the data. Use direct arrangements where they genuinely improve net cost, access, and member experience. Keep the functions that still add value. Strip out the ones that only add confusion. In a market as messy as prescription drugs, that may be the closest thing to elegance America is going to get.